Recognition places pharmaceutical excipients leader among the top 5% of companies globally, highlighting progress in emissions reduction, responsible sourcing, and sustainable supply chain practices
The program provides pharmaceutical manufacturers with auditable, primary emissions data and verified proof of a 30% CO? reduction across DFE Pharma’s lactose portfolio
The centre works with active pharmaceutical ingredients (APIs) and can utilize innovative concepts with model APIs
Under the deal, ViiV Healthcare will issue new shares to Shionogi for $2.125 billion and cancel Pfizer’s holding
Acute therapies continue to report strong growth compared to chronic ones.
Subscribe To Our Newsletter & Stay Updated
